Glycotope GmbH

Glycotope GmbH is a biotechnology company founded in 2001 and headquartered in Germany. The company is committed to improving the lives of cancer patients by developing uniquely tumor-specific monoclonal antibodies using a proprietary technology platform. Their expertise in glycobiology and antibody development allows them to advance first-in-class antibody-based therapeutics for (immuno)-oncology. The company has discovered over 200 GlycoTargets and has several antibodies against selected targets under development. These antibodies have superior tumor-specificity and are suitable for development in various modes of action including naked antibodies, bispecifics, antibody-drug-conjugates, cellular therapies, or fusion proteins. With a clear focus on advancing cancer treatment options, Glycotope is poised to make significant contributions to the field of oncology.